demonstrated that ablation of GSDMD, the potential downstream effector of NLRP3, dramatically prevented or ameliorated NOMID-induced inflammatory symptoms and disease progression (25–27), suggesting a potential clinical translational value of GSDMD in CAPS. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.